All News

In an additional post-hoc analysis, guselkumab demonstrated improvements at week 48, according to Janssen Pharmaceutical.

The treatment shows positive results in metastasis-free survival for men with non-metastatic hormone-sensitive prostate cancer, Pfizer and Astellas announce.

Shiela Plasencia, director of practice support at the Community Oncology Alliance, discussed COA’s new tool to help practices prepare for the Enhancing Oncology Model.

3D biofabrication models reflect increasing global awareness of the ethics of preclinical studies and an increased need for determining therapeutic efficacy differences.

Nick Ferreyros, managing director of policy, advocacy, and communications at the Community Oncology Alliance, discussed the Alliance’s efforts surrounding PBMs and 340B reform.

Retifanlimab-dlwr (Zynyz; Incyte) was granted FDA accelerated approval for metastatic or recurrent locally advanced Merkel cell carcinoma.

There is no single thing that can prevent all cancer risk, but there are 6 pillars of lifestyle that people can adopt to best prevent the disease.

Kandy Dunnigan, AAS, CPhT-Adv, a drug diversion analyst at Novant Health, discusses her role in the pharmacy.

Services include adherence assessments, health screenings, medication reconciliation, vaccine administration.

Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.

The primary outcome of the study includes an IGA score of 0 or 1, which indicated clear or almost clear skin, respectively, with a reduction, from baseline to week 16.

Blinded arms of the study will continue to evaluate the combination therapy with docetaxel vs docetaxel alone, Merck says.

John Beckner of National Community Pharmacists Association (NCPA) discusses how independent pharmacy plays a new role in primary care with Douglas Hoey, CEO of NCPA.

Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.

Educating patients, providers improves acceptance, trust as number of approvals, indications grows

The portfolio of oral oncology products has evolved over the past few years and so has the traditional model of distribution.

For the management of ovarian cancer, it has been observed in both cellular and animal models that curcumin suppresses cell proliferation and promotes apoptosis.

New access laws allow pharmacists to establish standing orders with specific physicians or follow blanket, statewide protocols.

The COVID-19 pandemic marginally affected the negative mental health of women more than men, according to a new study.

Purine metabolite xanthine, found in caffeinated beverages and food, affect cell differentiation, and new study results may lead to more knowledge about why diseases such as IBD develop.

Investigators estimate that the effectiveness was higher after 1 or 2 booster doses compared with the primary series alone.

Atea’s drug candidate is considered safe and effective against the viruses that cause COVID-19 and hepatitis C, according to new data presented at ICAR 2023.

Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.

Clinical decision support, packaging changes can help stop errors related to the HIV medication.

Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.

Emotional support greatly improved symptoms of psychological distress from the pandemic among pregnant women.

Most patients used nonproprietary drugs, which may contribute to the reduction of out-of-pocket costs for the treatment of invasive breast cancer.

This month, we spoke with Danielle Roman, PharmD, an oncology clinical pharmacy specialist with Allegheny Health Network.